NCT04309578

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

A Phase II Clinical Study of Trastuzumab in Combination With Capecitabine and Cisplatin (XP) in Patients With Tissue HER2-negative But Serum HER2-positive Advanced Gastric Cancer: XP+Samfenet

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancer

Detailed description

3-weekly/ 1cycle treatment * Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks * Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15) * Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1

Conditions

• Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Trastuzumab, Capecitabine and Cisplatin	* Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks * Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15) * Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1

Timeline

• Start date: 2020-03-12
• Primary completion: 2024-07-09
• Completion: 2024-12-13
• First posted: 2020-03-16
• Last updated: 2026-04-03

Locations

1 site across 1 country: South Korea